The extract of Celtis choseniana Nakai alleviates testosterone-induced benign prostatic hyperplasia through inhibiting 5α reductase type 2 and the Akt/NF-κB/AR pathway.
10.1016/S1875-5364(22)60178-X
- Author:
Geum-Lan HONG
1
;
Tae-Won KIM
1
;
Hui-Ju LEE
1
;
Yae-Ji KIM
1
;
Kyung-Hyun KIM
1
;
Ju-Young JUNG
2
Author Information
1. Department of Veterinary Medicine & Institute of Veterinary Science, Chungnam National University, Daejeon 34134, Republic of Korea.
2. Department of Veterinary Medicine & Institute of Veterinary Science, Chungnam National University, Daejeon 34134, Republic of Korea. Electronic address: jyjung@cnu.ac.kr.
- Publication Type:Journal Article
- Keywords:
5α-Reductase type 2;
Androgen receptor;
Apoptosis;
Benign prostate hyperplasia;
Celtis choseniana Nakai;
NF-κB
- MeSH:
Animals;
Cholestenone 5 alpha-Reductase/metabolism*;
Finasteride/adverse effects*;
Male;
NF-kappa B/genetics*;
Plant Extracts/therapeutic use*;
Prostatic Hyperplasia/drug therapy*;
Proto-Oncogene Proteins c-akt/genetics*;
Rats;
Rats, Sprague-Dawley;
Receptors, Androgen/metabolism*;
Testosterone;
Ulmaceae/metabolism*
- From:
Chinese Journal of Natural Medicines (English Ed.)
2022;20(7):518-526
- CountryChina
- Language:English
-
Abstract:
Benign prostatic hyperplasia (BPH) is a chronic male disease characterized by the enlarged prostate. Celtis chosenianaNakai (C. choseniana) is medicinally used to alleviate pain, gastric disease, and lung abscess. In this study, the effect of C. choseniana extract on BPH was investigated using testosterone-induced rats. Sprague Dawley rats were divided into five groups: control, BPH (testosterone 5 mg·kg-1), Fina (finasteride 2 mg·kg-1), and C. choseniana (50 and 100 mg·kg-1). After four weeks of TP treatment with finasteride or C. choseniana, prostate weights and DHT levels were measured. In addition, the prostates were histopathologically examined and measured for protein kinase B (Akt)/nuclear factor-κB (NF-κB)/AR signaling, proliferation, apoptosis, and autophagy. Prostate weight and epithelial thickness were reduced in the C. choseniana groups compared with that in the BPH group. The extract of C. choseniana acted as a 5α reductase inhibitor, reducing DHT levels in the prostate. Furthermore, the extract of C. choseniana blocked the activation of p-Akt, nuclear NF-κB activation and reduced the expression of AR and PSA compared with BPH. Moreover, the expression of Bax, PARP-1, and p53 increased, while the expression of bcl-2 decreased. The present study demonstrated that C. choseniana extract alleviated testosterone-induced BPH by suppressing 5α reductase and Akt/NF-κB activation, reducing AR signaling and inducing apoptosis and autophagy in the prostate. These results suggested that C. choseniana probably contain potential herbal agents to alleviate BPH.
